142 related articles for article (PubMed ID: 31774712)
21. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
[TBL] [Abstract][Full Text] [Related]
22. The investment case for cervical cancer elimination.
Tsu VD; Ginsburg O
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():69-73. PubMed ID: 28691328
[TBL] [Abstract][Full Text] [Related]
23. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
[TBL] [Abstract][Full Text] [Related]
24. CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide.
Senkomago V; Duran D; Loharikar A; Hyde TB; Markowitz LE; Unger ER; Saraiya M
Emerg Infect Dis; 2017 Dec; 23(13):S101-7. PubMed ID: 29155666
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus vaccination acceptance and hesitancy in South Africa: Research and policy agenda.
Ngcobo NJ; Burnett RJ; Cooper S; Wiysonge CS
S Afr Med J; 2018 Dec; 109(1):13-15. PubMed ID: 30606297
[TBL] [Abstract][Full Text] [Related]
27. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
28. Will HPV vaccination affect cervical cancer morbidity and mortality world-wide?
Luckett R; Feldman S
Hum Vaccin Immunother; 2016 Jun; 12(6):1373-4. PubMed ID: 27104494
[No Abstract] [Full Text] [Related]
29. Cervical Cancer Working Group report.
Konno R; Sagae S; Yoshikawa H; Basu PS; Hanley SJ; Tan JH; Shin HR
Jpn J Clin Oncol; 2010 Sep; 40 Suppl 1():i44-50. PubMed ID: 20870919
[TBL] [Abstract][Full Text] [Related]
30. The role of the human papillomavirus (HPV) vaccine in developing countries.
Kling M; Zeichner JA
Int J Dermatol; 2010 Apr; 49(4):377-9. PubMed ID: 20465688
[TBL] [Abstract][Full Text] [Related]
31. An analysis of key stakeholders' attitudes and beliefs about barriers and facilitating factors in the development of a cervical cancer prevention program in South Africa.
Francis SA; Leser KA; Esmont EE; Griffith FM
Afr J Reprod Health; 2013 Mar; 17(1):158-68. PubMed ID: 24069745
[TBL] [Abstract][Full Text] [Related]
32. Advocacy, communication, and partnerships: Mobilizing for effective, widespread cervical cancer prevention.
Wittet S; Aylward J; Cowal S; Drope J; Franca E; Goltz S; Kuo T; Larson H; Luciani S; Mugisha E; Schocken C; Torode J
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():57-62. PubMed ID: 28691332
[TBL] [Abstract][Full Text] [Related]
33. Issues and challenges in implementing cervical cancer screenings in the emergence of HPV vaccination in Thailand.
Juntasopeepun P; Davidson PM; Srisomboon J
Collegian; 2012; 19(1):45-50. PubMed ID: 22482282
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
35. Control of cancer of the cervix uteri. A WHO meeting.
Bull World Health Organ; 1986; 64(4):607-18. PubMed ID: 3490930
[TBL] [Abstract][Full Text] [Related]
36. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study.
Simms KT; Hanley SJB; Smith MA; Keane A; Canfell K
Lancet Public Health; 2020 Apr; 5(4):e223-e234. PubMed ID: 32057317
[TBL] [Abstract][Full Text] [Related]
37. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
Crager SE; Guillen E; Price M
Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
[TBL] [Abstract][Full Text] [Related]
38. Cervical cancer as a public health issue--what next?
Corusić A; Skrgatić L; Mahovlić V; Mandić V; Planinić P; Karadza M
Coll Antropol; 2010 Mar; 34(1):301-7. PubMed ID: 20432764
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.
Goldie SJ; Freedberg KA; Weinstein MC; Wright TC; Kuntz KM
Am J Med; 2001 Aug; 111(2):140-9. PubMed ID: 11498068
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
